Literature DB >> 12501867

ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).

.   

Abstract

Selective estrogen receptor modulators (SERMs) are synthetic compounds that bind estrogen receptors and produce agonistic activity in some tissues while acting as estrogen antagonists in other tissues. Although referred to collectively, their effects in different organs (eg, endometrium, urinary tract) are far from uniform. Much confusion exists about the indications for their use and the effects of these compounds. The purpose of this document is to review the use of SERMs for breast cancer risk reduction and skeletal protection as approved by the U.S. Food and Drug Administration (FDA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12501867     DOI: 10.1016/s0020-7292(02)00350-8

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

1.  [Effect of compound recipe Gengniankang on senile sexual hormone and expression of estrogen receptor in bone of climacteric female rats].

Authors:  Su-hui Wu; Jing-fen Sun; Shu-zhen Guo
Journal:  Chin J Integr Med       Date:  2005-09       Impact factor: 1.978

2.  Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.

Authors:  Mony Shuvy; Suzan Abedat; Ronen Beeri; Michael Valitsky; Sameh Daher; Miriam Kott-Gutkowski; Anca Gal-Moscovici; Jacob Sosna; Nalini M Rajamannan; Chaim Lotan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

Review 3.  Skeletal and nonskeletal effects of raloxifene.

Authors:  Oscar Gluck; Michael Maricic
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.